FDA fast-tracks Abbvie's lung cancer drug
![Photo: Abbvie / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13613141.ece/ALTERNATES/schema-16_9/doc7j5b09zppwzx40j8jda.jpg)
Abbvie starts out 2022 with positive news, as the US Food and Drug Administration (FDA) sees big potential in Abbvie's investigational antibody-drug conjugate, telisotuzumab vedotin.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.